For whoever owns UK recruitment for a clinical trial.
At a sponsor, a CRO with UK sites, or an academic clinical trials unit, in the UK or anywhere else. We follow every referral through to randomisation, and tell you which ones went nowhere and why.
What you'd use us for
- Panel count: how many members with the condition we hold near your sites, the same working day.
- Site choice by postcode district: where people with the condition live, and what would make taking part possible.
- Invitation testing: your protocol synopsis, information sheet, invitation and visit plan, reviewed by people who live with the condition before they're final.
- Referrals: members who pass your screening questions and say yes, with the yes recorded and a best time to call.
- Every patient followed to randomisation: one line per patient each week, randomisation checked against your own record, and the site hears first about anyone not yet reached, with its own note beside them. It's a record of where each patient is, never a score for the site.
"How many people with COPD have joined you near our sites in Leeds, Leicester and Glasgow, and how many would consider a clinical trial?"
What comes back
A free panel count, the same working day: how many members with COPD we hold near each site, by postcode district, broken down by age, sex, ethnicity and deprivation, and how many have told us they'd consider a clinical trial. It's a count of who has joined us, not a forecast of enrolment.
Sponsors and CROs
If your CRO drafts the documents, the CRO can send them to us and receive the report. Global protocols arrive fixed: what the UK team owns is the UK information sheet, the invitation, the site list and the recruitment plan, and that's where we work.
Academic clinical trials units
Our members are people living with the condition near where you're recruiting. We quote the whole clinical trial at one set price before anything starts, so it fits inside a grant, and universities usually can't recover VAT, so every quote shows the figure with VAT as well as without.
Already have a PPI group?
Keep it. A group of ten can't tell you how a thousand people with the condition would read your information sheet. That's the scale and breakdown we add.
First-in-human and rare disease
If your first clinical trial is in healthy volunteers, say so in the panel count and we'll tell you honestly whether our members can help. If it's in patients, the information sheet and the visit burden are exactly what members are good at.
For a condition with a few hundred UK patients, we don't pretend to hold 150 of them. We build a small group to order, patients or caregivers, and we'll report on a group as small as ten. Recruiting usually takes about four weeks, and the build is part of your quote, not charged on top.
Safety
Members are told when they join how to report a side effect to their doctor and to the MHRA's Yellow Card scheme. Every survey answer, voice note and video diary is screened by our team before it reaches you. Anything that mentions a side effect, a product complaint or a safety concern about a named medicine is passed to your pharmacovigilance contact within one working day, and we close every piece of work with a reconciliation log of what was passed on and when.
Why go first?
We haven't made a referral yet, so the first time, we carry the risk. Referral fees are capped. After the panel count, we commit to a number of referrals, and if we fall short, we refund the set-up fee pro rata. Success fees apply only to patients who came from our members.
What we don't claim
That following patients up raises enrolment: we haven't found controlled evidence that it does. It gives the team the facts, not a promised result.